Press releases

Company's Quincy Distribution Center approved as a sterilization site for its Cutting Balloon™ microsurgical dilatation device product line.

Company recognized for its achievements in lean manufacturing at its Minnesota facility

A live webcast and replay of the March 15th session will be available. Learn how to tune in.

Trial is designed to analyze "real-world" outcomes for patients with gastroesophageal reflux disease (GERD).

Johnson & Johnson trial results add to the extensive body of clinical evidence reinforcing the safety profile of Company’s TAXUS system.

Nine-month study data presented at the annual American College of Cardiology scientific session in Orlando.

(March 4, 2005) -- Boston Scientific Corporation (NYSE:BSX) today announced that it has completed its acquisition of Advanced Stent Technologies, Inc. (AST) of Pleasanton, California, for an...

(March 3, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events at the American College of Cardiology annual scientific session, which runs...

TAXUS OLYMPIC registry plans to enroll more than 30,000 patients at more than 600 centers in the United States, Europe and other international locations.

ATLAS clinical trial is the first trial using Boston Scientific's new Liberté™ coronary stent as a platform for its paclitaxel-eluting coronary stent system.

Announcement confirms the safety and efficacy of coil embolization for the treatment of ruptured and unruptured brain aneurysms.

A live webcast and replay of the Feb. 8th session will be available. Learn how to tune in for the presentation.

At a meeting with analysts and investors, Company provided ranges for both sales and earnings goals for the three-year period.

Next-generation stent system has been launched in 18 countries.

On February 1, Company will provide financial guidance for 2005, and financial goals for 2006 and 2007. Learn how to tune in.

A live webcast and replay of the January 25th session will be available. Learn how to tune in for the presentation.

Marks a major milestone for the Company and for the treatment of coronary artery disease.

Launch of TAXUS™ Liberté™ paclitaxel-eluting coronary stent system in 18 countries provides physicians state-of-the-art drug-eluting stent technology for the treatment of coronary artery disease.

The announcement was made by Jim Tobin, President and Chief Executive Officer, at the JPMorgan Healthcare Conference in San Francisco.

U.S. District Court in Delaware granted summary judgment of non-infringement in favor of Boston Scientific.

A live webcast and replay of the January 10th session will be available. Learn how to tune in for the presentation.

Jim Tobin, President and CEO, calls Company’s 2004 performance “nothing short of remarkable and speaks to a truly global effort."

Money is being directed to the Red Cross' International Response Fund.

Expansion of management structure is designed to position the Company for continued growth and success.

The transaction is expected to close early next year.